| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | Bryostatin 1 | GDSC1000 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | pac-1 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | paclitaxel | GDSC1000 | pan-cancer | AAC | -0.027 | 0.6 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |